Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

13.83
+1.209.50%
Post-market: 13.81-0.0217-0.16%19:39 EDT
Volume:3.68M
Turnover:50.61M
Market Cap:1.09B
PE:6.53
High:14.19
Open:13.09
Low:13.01
Close:12.63
52wk High:17.29
52wk Low:5.70
Shares:78.65M
Float Shares:72.22M
Volume Ratio:2.42
T/O Rate:5.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.12
EPS(LYR):1.87
ROE:82.56%
ROA:2.29%
PB:4.69
PE(LYR):7.40

Loading ...

U.S. Earnings Preview: After Market Close Aug. 27

Dow Jones
·
Aug 28

PagerDuty, Inc. Expected to Post Earnings of 31 Cents a Share - Earnings Preview

Reuters
·
Aug 26

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

GlobeNewswire
·
Aug 25

Annovis to Host Corporate Update Webinar on September 2, 2026

GlobeNewswire
·
Aug 25

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage

GlobeNewswire
·
Aug 25

LEADS BIOLABS-B (09887) Expands Phase II Study of Vilitrin (Opasotiumumab, PD-L1/4-1BB Bispecific Antibody, LBL-024) as First-Line Treatment for ESCC into Extension Phase

Stock News
·
Aug 25

Nanjing Leads Biolabs’ PD-L1/4-1BB Cancer Drug Wins Priority Review in China

TIPRANKS
·
Aug 21

Leads Biolabs-B Submits NDA for Velixin with NMPA, a Potential First-in-Class PD-L1/4-1BB Bispecific Antibody

Stock News
·
Aug 21

PagerDuty is Maintained at Buy by Truist Securities

Dow Jones
·
Aug 21

Truist Raises Price Target on PagerDuty to $13 From $11, Keeps Buy Rating

MT Newswires Live
·
Aug 20

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement

GlobeNewswire
·
Aug 20

CSPC Launches Phase Ib/II Trial of Novel PD-1/IL-15 Fusion Drug for Liver Cancer in China

TIPRANKS
·
Aug 19

Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

GlobeNewswire
·
Aug 18

PagerDuty is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Aug 14

Press Release: Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Dow Jones
·
Aug 14

RBC Capital Sticks to Its Hold Rating for PagerDuty (PD)

TIPRANKS
·
Aug 14

Press Release: PagerDuty to Report Second Quarter Fiscal Year 2027 Results on August 27, 2026

Dow Jones
·
Aug 14

PagerDuty to Report Fiscal Q2 Results After Market Close

Reuters
·
Aug 14

Press Release: Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 13

AKESO (09926) Gains NMPA Nod for Third Indication of Its First-in-Class Bispecific Antibody, Ivonescimab, in Frontline Squamous NSCLC

Stock News
·
Aug 12